We are working on upgrading our websites and despite our best endeavours have experienced census type calamities for almost a week now. Our apologies, we hope to have all problems resolved by Monday August 15th.


Any AUS or NZ company


Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z



Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:


Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names


Shareholder links

Our website ranking of MEB: rating 4
(4 out of 5)



Computershare Investor Services, Level 11 172 St Georges Terrace Perth WA 6000

Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 7 3229 9860
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000MEB8
Address: Level 4, 100 Albert Road South Melbourne VIC 3205
Tel:  +613 9692 7222 Fax: +613 9077 9233

Date first listed: 29/01/2001
Company Secretary: Mathew Watkins
Sector: Pharmaceuticals & Biotechnology Industry Group: XHJ
Activities: Development of diagnostic heart rate variability technology for mental health diagnosis

News & Events

Expand this box to read and print

The suspension of trading in the securities of Medibio Limited will be lifted immediately following the release by MEB of an announcement regarding its capital raising.


Commitments were received for $3.5 million placement at $0.01 per fully paid ordinary share. SPP were on the same terms, underwritten for $520,000. Issue price of $0.01, a 51.6% discount to the 5-day VWAP. Placement to be completed over two stages. ✓ Investors under the placement and Eligible shareholders under the SPP to be offered 1 free attaching option for each new share subscribed for, exercisable at $0.03 until an expiry date of 1 December 2021 and for which the Company will seek quotation on the ASX. Existing holders of convertible notes have agreed to early conversion of their notes for fully paid ordinary shares at a conversion price equal to the issue price under the Placement. Each noteholder will be offered 1 free New Option for each Share issued. Issue of securities under Stage 2 of the Placement, the SPP (including underwritten shortfall) and the early conversion of notes is subject to shareholder approval, to be sought at an EGM to be held in late August 2019.


The securities of Medibio Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of MEB, pending the release of an announcement regarding a capital raising.


we understand that on or about this date the company consolidated its shares 1 for 100


The suspension of trading in the securities of Medibio Limited (the "Company") will be lifted immediately following receipt of an announcement in relation to an agreement with John Hopkins Hospital. Security Code: MEB


name changed from Bioprospect Limited - was previously called MEDIA ASIA PACIFIC LIMITED which delisted from ASX on 31 August 1998 following the company's failure to lodge annual listing fees in respect of the year ended 30/06/99.



Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.


Company Updates

Post your comments here

Please read our Terms before posting comments.
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...



    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    09/11/2018Chris Indermaur200,000$0.040$8,000
    06/11/2018Andrew Maxwell216,002$0.044$9,434
    02/08/2017Andrew Maxwell26,000$0.380$9,880
    10/07/2017Peter Carlisle5,500$0.373$2,053
    18/04/2017Jack Cosentino100,000$0.370$37,000

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    Claude SolitarioManaging Director29/04/2014
    Steve SathreCFO01/01/2019
    Peter CarlisleIndependent Director05/06/2017
    Lisa HeineNon Exec Director29/08/2019
    Lisa IdeNon Exec Director29/08/2019
    Liwanag OjalaNon Exec Director29/08/2019
    Melanie LeydinNon Exec Director22/02/2019

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    David KaysenChairman, CEO02/11/201808/01/2020
    Franklyn PrendergastNon Exec Director27/01/201629/08/2019
    Michael PhelpsNon Exec Director05/06/201729/08/2019
    Patrick KennedyNon Exec Director04/07/201729/08/2019
    Andrew MaxwellNon Exec Director01/02/201722/02/2019
    Brian MowerCFO24/04/201701/01/2019
    Chris IndermaurNon Exec Chairman02/04/201531/12/2018
    Jack CosentinoManaging Director, CEO16/02/201728/08/2018
    Adam DarkinsDeputy Chairman, Non Exec Director19/07/201719/01/2018
    Kris KnauerExecutive Director, CFO02/07/201413/10/2017
    Robert LeesCFO28/09/201224/04/2017
    James CampbellNon Exec Director07/09/201430/09/2016
    Vince FayadNon Exec Chairman29/04/201407/04/2015
    Silvi ElkhouriNon Exec Director15/11/201308/09/2014
    Claude SolitarioExecutive Director29/04/201408/09/2014
    Peter MayNon Exec Director01/11/200830/06/2014
    Benjamin CooperExecutive Director10/04/201229/04/2014
    Winton WilleseeChairman, Non Exec Director16/09/201115/11/2013
    Peter PellegrinoManaging Director01/11/200919/11/2012
    Colin JohnstonCFO01/03/200428/09/2012
    Jacob KhouriNon Exec Director16/02/201118/09/2012

    Date of first appointment, title may have changed.